JP Morgan Chase’s Oragenics OGEN Stock Holding History

JP Morgan Chase’s Portfolio OGEN Stock Details OGEN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-681	Closed	-$2.6K	–	7632
2025 Q2	$2.6K	Buy	681 +675	+11,250%	+$3.42K	﹤0.01%	6501
2025 Q1	$39	Sell	6 -4	-40%	-$35	﹤0.01%	7023
2024 Q4	$115	Buy	+10	New	+$102	﹤0.01%	6990

Other funds holding OGEN

DRW Securities Chicago, Illinois $7.21B AUM 20.54% 1-Year Est. Return

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Allworth Financial Folsom, California $24.7B AUM 15.55% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Harbour Investments Madison, Wisconsin $6.48B AUM 18.23% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

JP Morgan Chase's OGEN Position: Q3 2025 in Review

JP Morgan Chase sold out of Oragenics (OGEN) in Q3 2025, closing a stake of 681 shares — an estimated $2.6K sold.

JP Morgan Chase first reported a position in OGEN in Q4 2024 and held it in 3 quarters. The position peaked at $2.6K in Q2 2025. 16 funds tracked by Wall St. Rank hold OGEN as of Q3 2025.

JP Morgan Chase reported no remaining Oragenics position as of Q3 2025 after selling out during the quarter.
JP Morgan Chase sold 681 Oragenics shares in Q3 2025, an estimated $2.6K.
JP Morgan Chase first reported a position in Oragenics in Q4 2024 and held it in 3 quarters.
JP Morgan Chase's Oragenics position peaked at $2.6K in Q2 2025.
16 funds tracked by Wall St. Rank held Oragenics as of Q3 2025.

Based on JP Morgan Chase's 13F filing for Q3 2025, filed 7 Nov 2025.